Core Viewpoint - Doximity reported better-than-expected Q3 results but provided lower revenue guidance for Q4 and full-year 2026, leading to a significant drop in stock price during after-hours trading [2][3][4][6] Financial Performance - Doximity's Q3 revenue reached $185.05 million, exceeding estimates of $182.20 million, representing a 10% year-over-year increase [2] - Adjusted earnings for the quarter were 46 cents per share, slightly above the expected 45 cents per share [2] User Engagement and Product Development - The company reported over one million quarterly active prescribers and a record 720,000 users for its workflow products, indicating strong user engagement [3] - Doximity's AI products have gained traction, with over 300,000 users, enhancing the platform's utility [3] Future Guidance - For Q4, Doximity expects revenue between $143 million and $144 million, below the consensus estimate of $150.23 million [4] - The full-year 2026 revenue guidance was narrowed to a range of $642.5 million to $643.5 million from a previous range of $640 million to $646 million [4] Share Repurchase Program - The board of Doximity authorized a share repurchase program to buy back up to $500 million of the company's common stock [4] Stock Performance - Following the earnings report and lowered guidance, Doximity's stock fell by 33.22% in after-hours trading, with shares priced at $22.25 [6]

Revenue and Growth - Revenue for the three months ended December 31, 2025, was $185.1 million, a 10% increase from $168.6 million in the same period of 2024[140] - For the nine months ended December 31, 2025, revenue reached $499.5 million, reflecting a 16% growth compared to $432.1 million in 2024[140] - Revenue for the three months ended December 31, 2025 increased by $16.5 million (10%) compared to the same period in 2024, primarily driven by a $13.1 million increase in subscription revenue[172] - Subscription revenue for the nine months ended December 31, 2025 increased by $60.9 million, with $15.4 million from new subscription customers and $45.5 million from existing customers[172] - Approximately 95% of the company's revenue for the three and nine months ended December 31, 2025 was derived from subscription customers[172] Profitability and Income - Net income for the three months ended December 31, 2025, was $61.6 million, down from $75.2 million in 2024, while adjusted EBITDA was $111.4 million, up from $102.0 million[140] - Net income for the three months ended December 31, 2025 was $61.6 million, a decrease of $13.6 million (18%) compared to the same period in 2024[170] - Gross profit for the three months ended December 31, 2025 was $166.4 million, an increase of $11.9 million (8%) compared to the same period in 2024[172] Customer Metrics - The number of customers with trailing 12-month subscription revenue greater than $500,000 increased to 126 in 2025 from 115 in 2024, accounting for approximately 84% of total revenue[143] - The net revenue retention rate decreased to 112% in 2025 from 117% in 2024, indicating a slight decline in revenue growth from existing customers[145] Expenses - Research and development expenses are expected to increase as the company continues to grow its platform and product offerings[163] - Research and development expenses for the three months ended December 31, 2025 increased by $12.2 million (54%) compared to the same period in 2024, driven by stock-based compensation and personnel costs[174] - Sales and marketing expenses for the three months ended December 31, 2025 increased by $3.7 million (10%) compared to the same period in 2024, primarily due to stock-based compensation[177] - General and administrative expenses for the three months ended December 31, 2025 increased by $4.1 million (30%) compared to the same period in 2024, driven by legal expenses and stock-based compensation[179] - Total operating expenses for the nine months ended December 31, 2025 were $258.5 million, an increase of $46.9 million (22%) compared to the same period in 2024[170] Cash Flow and Financial Position - Free cash flow for the nine months ended December 31, 2025, was $210.2 million, compared to $169.8 million in 2024, demonstrating improved cash generation[154] - Net cash provided by operating activities for the nine months ended December 31, 2025, was $216.9 million, an increase from $174.8 million in the same period in 2024[193][194] - Cash provided by investing activities was $9.2 million for the nine months ended December 31, 2025, primarily from marketable securities[196] - Cash used in financing activities was $370.9 million for the nine months ended December 31, 2025, mainly due to common stock repurchases of $341.1 million[198] - As of December 31, 2025, the company had cash and cash equivalents and marketable securities totaling $735.1 million[187] Share Repurchase and Taxation - The company repurchased 8,648,145 shares of Class A common stock for an aggregate purchase price of $417.0 million as of December 31, 2025, with $83.0 million remaining authorized for repurchase[188] - The effective income tax rate for the company differs from the U.S. statutory tax rate of 21.0% primarily due to stock-based compensation related tax benefits[168] Other Income and Charges - Other income, net for the three months ended December 31, 2025, decreased by 10% to $8.9 million compared to the same period in 2024, primarily due to lower interest income[182][183] - Other income, net for the nine months ended December 31, 2025, increased by 7% to $27.8 million compared to the same period in 2024, driven by a higher average portfolio balance[184] - Provision for income taxes for the three months ended December 31, 2025, increased by 31% to $19.2 million compared to the same period in 2024[185] - The impairment charge for the nine months ended December 31, 2024, was $2.3 million due to a sublease of the Curative office space in Irving, Texas[181] Business Strategy - The business model focuses on providing digital tools for medical professionals, enhancing productivity and patient care[138] - The company aims to expand its market presence and enhance its product offerings through strategic investments and innovations[139] Market Sensitivity - A hypothetical 100 basis point increase in interest rates would have resulted in a decrease of $4.6 million in the market value of cash equivalents and marketable securities as of December 31, 2025[205]

Financial Performance - Total revenues for Q3 FY2026 reached $185.1 million, representing a 10% increase year-over-year from $168.6 million[5] - Net income for the quarter was $61.6 million, with a margin of 33.3%, down from 44.6% in the same quarter last year[5] - Adjusted EBITDA was $111.4 million, reflecting a 9% year-over-year increase, with an adjusted EBITDA margin of 60.2%[5] - The company reported a diluted net income per share of $0.31, down from $0.37 in the same quarter last year[5] - Net income for Q3 2025 was $61,558, a decrease of 18.2% from $75,196 in Q3 2024[15] - Non-GAAP gross profit for Q3 2025 was $111,396, representing a gross margin of 60.2%, compared to 60.5% in Q3 2024[20] - Total revenue for Q3 2025 was $185,053, up from $168,603 in Q3 2024, reflecting a growth of 9.5%[20] - Adjusted EBITDA for Q3 2025 was $111,396, compared to $102,038 in Q3 2024, indicating a year-over-year increase of 9.3%[20] - GAAP operating income for Q3 2025 was $71,896,000, down from $79,925,000 in Q3 2024, indicating a decline of 10.4%[22] - Non-GAAP net income margin for Q3 2025 was 49.3%, down from 54.2% in Q3 2024[22] Cash Flow and Assets - Operating cash flow for the quarter was $60.9 million, a decrease of 7% year-over-year, while free cash flow was $58.5 million, down 8%[5] - Free cash flow for the nine months ended December 31, 2025, was $210,226, an increase from $169,760 in the same period of 2024[20] - Cash and cash equivalents at the end of the period were $64,838, down from $165,270 at the end of Q3 2024[15] - Total assets as of December 31, 2025, were $1.157 billion, down from $1.264 billion as of March 31, 2025[11] Guidance and Stock Repurchase - Doximity updated its revenue guidance for Q4 FY2026 to between $143 million and $144 million, and for the full fiscal year to between $642.5 million and $643.5 million[5] - The company authorized a stock repurchase program of up to $500 million for Class A common stock, with no expiration date[4] Research and Development - Research and development expenses increased to $34.6 million for the quarter, compared to $22.4 million in the same period last year[13] - Research and development expenses for Q3 2025 were $34,595,000, up from $22,421,000 in Q3 2024, marking a significant increase of 54.2%[21] Customer Metrics - The number of quarterly active prescribers exceeded 1 million, with workflow products reaching a record 720,000 users, and AI products surpassing 300,000 users[3] - The net revenue retention rate is a key metric reflecting customer renewals and expansions, directly tied to revenue growth[19] - The number of customers with trailing 12-month subscription revenue greater than $500,000 is a significant indicator of business scale[19] Expenses - The company incurred stock-based compensation expenses of $33,546 in Q3 2025, up from $19,368 in Q3 2024[20] - Total GAAP cost of revenue for Q3 2025 was $18,701,000, compared to $14,181,000 in Q3 2024, reflecting an increase of 32.9%[21] - Non-GAAP sales and marketing expense for Q3 2025 was $31,197,000, slightly higher than $30,853,000 in Q3 2024, indicating a growth of 1.1%[21]

Core Viewpoint - Doximity, Inc. operates a cloud-based digital platform for medical professionals in the U.S., focusing on collaboration, patient care coordination, virtual visits, and career management, positioning itself as a significant player in the healthcare technology sector [1] Price Target Trends - The consensus price target for Doximity's stock has decreased over the past year, with the average target falling from $60.56 last year to $55.60 last quarter, and further down to $53.50 last month, indicating a more conservative outlook from analysts [2][6] Ownership Structure - Doximity has substantial institutional and insider ownership, with 87.2% of shares held by these entities, which may enhance stock stability and bolster investor confidence [3][6] Analyst Ratings - Doximity has received a Zacks Rank 1 (Strong Buy) upgrade, reflecting optimism regarding its earnings prospects and suggesting potential upward movement in stock price despite the declining consensus price targets [4][6] Market Comparisons - Recent analyses have compared Doximity with other service-oriented companies, focusing on valuation, profitability, and institutional ownership, which aids investors in understanding Doximity's market position and future potential [5]

Market Analysis by covering: Phreesia Inc, Doximity Inc, Waystar Holding Corp. Read 's Market Analysis on Investing.com ...

Core Insights - Advancements in artificial intelligence (AI) are significantly enhancing patient care, reducing healthcare costs, and improving outcomes in the medical technology industry [1] - Generative AI is transitioning from a conceptual promise to practical applications in medical technology [1] Industry Developments - AI is expediting all phases of research and development, including generative design, virtual testing, clinical trials, and regulatory documentation [2] - The FDA is promoting the development of innovative medical devices that incorporate AI [2] Company Performance: Tempus AI (TEM) - Tempus has seen a stock increase of 27.2% over the past year, while Doximity's stock has declined by 32.8% [6] - The company is developing advanced AI algorithms and diagnostic software, collaborating with Northwestern University's Abrams Center for Alzheimer's research [7] - Tempus has received two FDA 510(k) clearances for its cardiac imaging platform and ECG-Low EF software [8] - In Q3 2025, Tempus achieved positive adjusted EBITDA of $1.5 million, with gross profit rising to $209.9 million, a 98.4% year-over-year increase [11] - EPS for 2025 is projected to be a loss of 64 cents, reflecting a 59.5% improvement from 2024 [15] Company Performance: Doximity (DOCS) - Doximity is well-positioned for AI adoption, embedding AI across its workflows and benefiting from a recent acquisition of Pathway Medical Inc. [9][13] - The company reported a 55% adjusted EBITDA margin and a 39% net income margin in fiscal 2025, with $267 million in free cash flow [14] - EPS for fiscal 2026 is projected to be $1.56, indicating a 9.9% improvement from fiscal 2025 [16] Valuation Comparison - Tempus has a forward 12-month price-to-sales (P/S) ratio of 7.24, while Doximity's is 10.38, indicating Doximity is trading at a premium [17] Conclusion - Doximity appears better positioned than Tempus, with deep AI integration, strategic acquisitions, and strong profitability metrics [18] - Tempus is recognized for its expanding AI capabilities and recent profitability milestone, indicating long-term potential in precision medicine [19]

Company Performance - Doximity (DOCS) closed at $38.96, down 3.56% from the previous trading session, underperforming the S&P 500's gain of 0.41% [1] - The company's shares have decreased by 8.66% over the past month, while the Medical sector lost 0.74% and the S&P 500 gained 0.38% during the same period [1] Upcoming Earnings - Doximity is set to release its earnings report on February 5, 2026, with an expected EPS of $0.44, reflecting a 2.22% decline compared to the same quarter last year [2] - Revenue is anticipated to be $181.03 million, which is a 7.37% increase from the prior-year quarter [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at $1.56 per share, with revenue expected to reach $645.29 million, indicating increases of 9.86% and 13.13% respectively from the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Doximity are crucial as they indicate shifts in near-term business trends, with positive revisions suggesting confidence in the company's performance [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks Doximity as 1 (Strong Buy), reflecting strong potential for outperformance [6] Valuation Metrics - Doximity has a Forward P/E ratio of 25.82, which is lower than the industry average of 27.99, indicating a valuation discount [7] - The company also has a PEG ratio of 1.36, compared to the industry average PEG ratio of 2.33, suggesting favorable growth prospects relative to its valuation [7] Industry Context - The Medical Info Systems industry, which includes Doximity, holds a Zacks Industry Rank of 82, placing it in the top 34% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1, highlighting the strength of the Medical Info Systems sector [8]

Core Viewpoint - Doximity (DOCS) has received a Zacks Rank 1 (Strong Buy) upgrade, indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in a company's earnings picture, with the consensus of EPS estimates from analysts being a key component [1][2]. - An increase in earnings estimates is strongly correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4]. Business Improvement Indicators - The upgrade in Doximity's rating suggests an improvement in the company's underlying business, which is expected to lead to higher stock prices as investors respond positively [5][10]. - For the fiscal year ending March 2026, Doximity is projected to earn $1.56 per share, with a 2% increase in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of stocks covered by Zacks receive a "Strong Buy" rating, indicating superior earnings estimate revisions and potential for market-beating returns [9][10].

Core Insights - Telehealth services offer convenience and potential savings for both physicians and patients, yet companies like Teladoc Health and Doximity have struggled in recent years [1][2] Group 1: Telehealth Market Dynamics - Medicare's reimbursement for telehealth services is set to expire on January 31, limiting coverage to specific cases, which is expected to reduce demand for telehealth [5][8] - The early pandemic years saw increased accessibility to telemedicine, but the upcoming changes in Medicare policy may reverse some of these gains [4] Group 2: Company Performance Outlook - Teladoc is anticipated to experience continued weak performance in 2026, with slow revenue growth and ongoing profitability challenges, exacerbated by the Medicare changes [6][7] - Doximity, while less affected by Medicare changes due to its broader service offerings, still faces a dim outlook in the current market environment [8][10] - Teladoc's international expansion shows some promise, but the company faces significant challenges that may hinder its recovery [9]

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. U.S. equity markets experienced a quarter shaped by optimism around potential monetary easing and caution related to economic growth and valuations. Early gains were driven by strong AI-related earnings and the US Federal Reserve’s rate cut in October. However, market sentiment cooled later in the quarter due to mixed signals from the Fed regardi ...